AR052142A1 - Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma - Google Patents

Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma

Info

Publication number
AR052142A1
AR052142A1 ARP050104839A ARP050104839A AR052142A1 AR 052142 A1 AR052142 A1 AR 052142A1 AR P050104839 A ARP050104839 A AR P050104839A AR P050104839 A ARP050104839 A AR P050104839A AR 052142 A1 AR052142 A1 AR 052142A1
Authority
AR
Argentina
Prior art keywords
enteric coated
ixabepilona
administration
preparation
same
Prior art date
Application number
ARP050104839A
Other languages
English (en)
Inventor
Ismat Ullah
Gary James Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR052142A1 publication Critical patent/AR052142A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Una perla recubierta entérica que comprende Ixabepilona, un compuesto que tiene una estructura de formula (1). También una cápsula que comprende una multitud de perlas recubiertas entéricas. Además, se describe un método de preparacion de la perla recubierta entérica y un método de tratamiento de cáncer u otras enfermedades proliferativas que usa la perla recubierta entérica.
ARP050104839A 2004-11-18 2005-11-17 Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma AR052142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
AR052142A1 true AR052142A1 (es) 2007-03-07

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104839A AR052142A1 (es) 2004-11-18 2005-11-17 Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma

Country Status (26)

Country Link
US (1) US20060153917A1 (es)
EP (2) EP1817013B1 (es)
JP (1) JP2008520696A (es)
KR (1) KR20070084325A (es)
CN (1) CN101083978A (es)
AR (1) AR052142A1 (es)
AT (1) ATE397442T1 (es)
AU (1) AU2005306464A1 (es)
BR (1) BRPI0518286A2 (es)
CA (1) CA2588400A1 (es)
DE (1) DE602005007376D1 (es)
DK (1) DK1817013T3 (es)
ES (1) ES2306278T3 (es)
HK (1) HK1106713A1 (es)
HR (1) HRP20080349T3 (es)
IL (1) IL183116A0 (es)
MX (1) MX2007005763A (es)
NO (1) NO20072388L (es)
PE (1) PE20061058A1 (es)
PL (1) PL1817013T3 (es)
PT (1) PT1817013E (es)
RU (1) RU2349319C1 (es)
SI (1) SI1817013T1 (es)
TW (1) TW200631609A (es)
WO (1) WO2006055740A1 (es)
ZA (1) ZA200703955B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
EP2544541B1 (en) * 2010-03-12 2014-10-08 Genzyme Corporation Combination therapy for treating breast cancer
WO2012047802A2 (en) * 2010-10-01 2012-04-12 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
KR101809305B1 (ko) 2011-02-11 2017-12-14 제트엑스 파마 엘엘씨 다중미립자 l-멘톨 제제 및 관련 방법
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
RS58325B1 (sr) 2013-04-23 2019-03-29 Zx Pharma Llc Enterosolventno obloženi višečestični preparat sa proteinskom sub-oblogom

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
CA2266519C (en) * 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
EP0941227B2 (de) * 1996-11-18 2009-10-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
EP1201666A3 (de) * 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Seitenkettenmodifizierte Epothilone
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
ATE295151T1 (de) * 1998-10-01 2005-05-15 Powderject Res Ltd Sprühbeschichtete mikropartikel für nadellose spritzen
EE200100431A (et) * 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
HUP0200076A3 (en) * 1999-02-22 2003-01-28 Bristol Myers Squibb Co C-21 modified epothilones, process for their preparation, pharmaceutical compositions containing them
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
YU26102A (sh) * 2000-08-09 2004-12-31 Panacea Biotec Limited Nove farmaceutske smese antituberkuloznih lekova i postupak za njihovo dobijanje
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
PL362225A1 (en) * 2000-09-22 2004-10-18 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Triazolo-epothilones
ATE279552T1 (de) 2000-09-26 2004-10-15 Enthone Omi Deutschland Gmbh Verfahren zur selektiven metallisierung dielektrischer materialien
BRPI0206509B8 (pt) * 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
WO2002062338A1 (en) * 2001-01-25 2002-08-15 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EP1368030A1 (en) * 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
HUP0303175A2 (hu) * 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP1392664A4 (en) * 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Ｊｓｒ株式会社 ネガ型感放射線性樹脂組成物
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ES2337134T3 (es) * 2002-03-12 2010-04-21 Bristol-Myers Squibb Company Derivados de c3-ciano-epotilona.
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
EP1551425A4 (en) * 2002-10-09 2006-09-20 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
DK1817013T3 (da) 2008-10-13
KR20070084325A (ko) 2007-08-24
WO2006055740A1 (en) 2006-05-26
ZA200703955B (en) 2008-08-27
NO20072388L (no) 2007-06-14
PT1817013E (pt) 2008-08-07
MX2007005763A (es) 2007-07-20
HK1106713A1 (en) 2008-03-20
PL1817013T3 (pl) 2009-01-30
US20060153917A1 (en) 2006-07-13
EP1817013A1 (en) 2007-08-15
ES2306278T3 (es) 2008-11-01
ATE397442T1 (de) 2008-06-15
BRPI0518286A2 (pt) 2008-11-11
JP2008520696A (ja) 2008-06-19
EP1817013B1 (en) 2008-06-04
DE602005007376D1 (de) 2008-07-17
CA2588400A1 (en) 2006-05-26
CN101083978A (zh) 2007-12-05
SI1817013T1 (sl) 2008-12-31
PE20061058A1 (es) 2006-10-13
AU2005306464A1 (en) 2006-05-26
HRP20080349T3 (en) 2009-01-31
RU2349319C1 (ru) 2009-03-20
IL183116A0 (en) 2007-09-20
EP1958625A1 (en) 2008-08-20
TW200631609A (en) 2006-09-16

Similar Documents

Publication Publication Date Title
AR052142A1 (es) Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
WO2007034188A3 (en) Chemo-immunotherapy method
DE60127977D1 (de) Verfahren zur herstellung von zähen, wärmehärtenden gegenständen und die wärmehärtenden gegenstände so hergestellt
DE60101232D1 (de) Elektronenemittierende Quelle, Baugruppe und Verfahren zu deren Herstellung
DE69920945D1 (de) Verfahren zur herstellung von arzneistoffpartikeln
DE602004024902D1 (de) Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
DE60322412D1 (de) Pharmazeutische feste Dispersionen von Modafinil-Verbindungen
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
DE60311990D1 (de) Verfahren zur herstellung eines virus inaktivierten thrombin präparates
NO20072668L (no) Ny kombinasjon
DE60105209D1 (de) Verfahren zur Herstellung von niedrig substituierter Hydroxypropylcellulose-Partikeln
ATE417608T1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
PL359208A1 (en) New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
ECSP045232A (es) Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral
DE50211253D1 (de) Verfahren zur Herstellung von Makrokapseln
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
DE602004023534D1 (de) Verfahren zur herstellung von optisch aktivem 2-alkylcystein, derivate davon und herstellungsverfahren
DE50303513D1 (de) Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung
DE60027754D1 (de) Verfahren zur herstellung von photolumineszenten polarisatoren
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat

Legal Events

Date Code Title Description
FB Suspension of granting procedure